SEOUL, Aug. 10 (Korea Bizwire) – South Korean drugmaker SK Bioscience Co. has won an approval to conduct the phase three clinical trial of its COVID-19 vaccine candidate, drug authorities said Tuesday. The Ministry of Food and Drug Safety said GBP510, under development by SK Bioscience, a unit of the country’s No. 2 family-controlled conglomerate [...]
SEOUL, June 21 (Korea Bizwire) — SK Bioscience Co., a major South Korean pharmaceutical firm, said Monday it plans to invest 150 billion won (US$132 million) through 2024 to expand its production capacity of COVID-19 vaccines. SK Bioscience said the investment is meant to increase the production capacity of the production line based in Andong, [...]
SEOUL, May 23 (Korea Bizwire) – South Korea, touted as one of most successful countries in containing the new coronavirus pandemic without lockdowns, is gearing up for its next step to emerge as a global vaccine hub, with four COVID-19 vaccines already being or set to be produced here. The country’s vision to become a [...]
SEOUL, March 18 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. made a splash in its debut on the main bourse Thursday, closing at more than two times its initial public offering (IPO) price. Instantly after the opening bell, its stock price soared to the daily permissible ceiling of 169,000 won (US$149.43), up [...]
SEOUL, March 10 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. drew a record 64 trillion won (US$56 billion) in investor deposits during a two-day subscription period for its share sale, company officials said Wednesday. According to the officials, the deposits for SK Bioscience’s initial public offering (IPO) surpassed the two previous records [...]
SEOUL, March 9 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. on Tuesday kicked off a two-day public subscription for its initial public offering (IPO), seen as a high-profile share sale during the first half. SK Bioscience, a unit of South Korea’s No. 2 family-controlled conglomerate SK Group, has allowed individual investors to [...]
GAITHERSBURG, Md., Feb. 15 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement. In addition to the already existing manufacturing arrangement, SK Bioscience has obtained a license to manufacture and [...]
GAITHERSBURG, Md. and SEOUL, South Korea, Aug. 13 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and SK bioscience, a vaccine business subsidiary of SK Group, today announced a development and supply agreement for the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, for [...]
SEOUL, July 21 (Korea Bizwire) — South Korea’s SK Bioscience inked a deal with global pharmaceutical company AstraZeneca to supply a candidate material for a coronavirus vaccine, the local biotech company said Tuesday. The letter of intent (LOI) reached between the two companies and the Ministry of Health and Welfare calls for close cooperation on [...]
SEOUL, May 19 (Korea Bizwire) – South Korean companies have received funds from the Bill & Melinda Gates Foundation, one of the world’s largest private foundations, to research treatment for COVID-19 after South Korea became a model case in containing the pandemic, with high potential in the information technology (IT) and biopharma industries. SK Bioscience, a local [...]